Redesigning a large-scale clinical trial in response to negative external trial results: The CAMUS study of phytotherapy for benign prostatic hyperplasia

Clinical Trials

Volumn 6, Issue 6, 2009, Pages 628-636

  Lee, Jeannette ^a   Andriole, Gerald ^b   Avins, Andrew ^c   Crawford, E David ^d   Foster, Harris ^e   Kaplan, Steven ^f   Kreder, Karl ^g   Kusek, John ^h   McCullough, Andrew ⁱ   McVary, Kevin ^j   Melatha, Sreeleth ^k   Naslund, Michael ^l   Nickel, J Curtis ^m   Nyberg, Leroy ^h   Roehrborn, Claus ⁿ   Williams, O Dale ^k   Barry, Michael ^o  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c DIVISION OF RESEARCH   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g UNIVERSITY OF IOWA   (United States)

^h NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

ⁱ NEW YORK UNIVERSITY   (United States)

^j NORTHWESTERN UNIVERSITY   (United States)

^k University of Alabama at Birmingham   (United States)

^l UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^m QUEEN S UNIVERSITY   (Canada)

ⁿ UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^o HARVARD MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; PLACEBO; PYGEUM AFRICANUM EXTRACT; SABAL EXTRACT;

ALTERNATIVE MEDICINE; ARTICLE; BARK; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; FRUIT; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHYTOTHERAPY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ADRENERGIC ALPHA-ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FRUIT; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PHYTOTHERAPY; PLANT BARK; PLANT EXTRACTS; PROSTATIC HYPERPLASIA; PYGEUM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SERENOA;

EID: 77149124569     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774509352199     Document Type: Article

References (24)

1. Jacobsen SJ, Girman CJ, Guess HA, et al. New diagnostic and treatment guidelines for benign prostatic hyperplasia. Potential impact in the United States. Arch Intern Med 1995;155:477-81.
2. Litman HJ, McKinlay JB. The future magnitude of urological symptoms in the USA: projections using the Boston Area Community Health survey. BJU Int 2007;100:820-5.
3. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia. Chapter 1. Diagnosis and treatment recommendations. J Urol 2003;170:530-47.
4. Roehrborn CG, Nuckholls JG, Wei JT, Steers W. The benign prostatic hyperplasia registry and patient survey: study design, methods and patient baseline characteristics. BJU Int 2007;100:813-9.
5. McConnell JD, Brusketwitz R, Walsh P, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-98.
6. Bautista OM, Kusek JW, Nyberg LM, et al. Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial. Control Clin Trials 2003;24:224-43.
7. Gardiner P, Graham R, Legedza AT, et al. Factors associated with herbal therapy use by adults in the United States. Altern Ther Health Med 2007;13:22-9.
8. Fourcade RO, Theret N, Taieb C. Profile and management of patients treated for the first time for lower urinary tract symptoms/benign prostatic hyperplasia in four European countries. BJU Int 2008;101:1111-8.
9. Dedhia RC, McVary KT. Phytotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2008;179:2119-25.
10. Gerber GS. Saw palmetto for the treatment of men with lower urinary tract symptoms. J Urol 2000;163:1408-12.
11. Ishani A, MacDonald R, Nelson D, et al. Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis. Am J Med 2000;109:654-64.
12. Tacklind J, MacDonald R, Turks I, Wilt TJ. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2009: CD001423.
13. Wilt T, Ishani A, Mac Donald R. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2002: CD001423.
14. Wilt T, Ishani A, MacDonald R, et al. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev 2002: CD001044.
15. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
16. Bent S, Kane C, Shinohara K, Neuhaus J, et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med 2006;354:557-66.
17. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. JAMA 2002;287:1807-14.
18. Turner RB, Bauer R, Woelkart K, et al. An evaluation of Echinacea angustifolia in experimental rhinovirus infections. N Engl J Med 2005;353:341-8.
19. Sampson W. Studying herbal remedies. N Engl J Med 2005;353:337-9.
20. DiPaola RS, Morton RA. Proven and unproven therapy for benign prostatic hyperplasia. N Engl J Med 2006;354:632-4.
21. Habib FK, Wyllie MG. Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract. Prostate Cancer Prostatic Dis 2004;7:195-200.
22. Clark RV, Hermann DJ, Cunningham GR, et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5-alpha-reductase inhibitor. J Clin Endocrinol Metab 2004;89:2179-84.
23. Breitner JC, Martin BK, Meinert CL. The suspension of treatments in ADAPT: concerns beyond the cardiovascular safety of celecoxib or naproxen. PLoS Clin Trials 2006; 1: e41.
24. Nissen SE. ADAPT: the wrong way to stop a clinical trial. PLoS Clin Trials 2006; 1: e35.